Skip to content

Which 36 life-saving drugs are exempted from BCD?

Here is the list of 36 life-saving medicines and 37 more medicines along with 30 new patient assistance programs exempted from customs duty. Latest
Which 36 life-saving drugs are exempted from BCD?
Which 36 life-saving drugs are exempted from BCD?

Finance Minister Nirmala Sitharaman recently announced that 36 life-saving drugs, including essential medicines for cancer and other rare diseases, would be exempt from basic customs duty. This decision was made during her Budget 2025 speech.

She also shared that 37 more medicines would be added to this list. Additionally, the government will set up 200 cancer daycare centers in government hospitals across all districts within the next three years.

List of 36 life-saving medicines exempted from custom duty

S. No.Drug Name
1Onasemnogene abeparvovec
2Asciminib
3Mepolizumab
4Pegylated Liposomal Irinotecan
5Daratumumab
6Daratumumab subcutaneous
7Teclistamab
8Amivantamab
9Alectinib
10Risdiplam
11Obinutuzumab
12Polatuzumab vedotin
13Entrectinib
14Atezolizumab
15Spesolimab
16Velaglucerase Alpha
17Agalsidase Alfa
18Rurioctocog Alpha Pegol
19Idursulphatase
20Alglucosidase Alfa
21Laronidase
22Olipudase Alfa
23Tepotinib
24Avelumab
25Emicizumab
26Belumosudil
27Miglustat
28Velmanase Alfa
29Alirocumab
30Evolocumab
31Cystamine Bitartrate
32CI-Inhibitor injection
33Inclisiran
34Agalsidase Beta
35Imiglucerase
36Eptacog alfa activated recombinant coagulation factor VIIa

Sitharaman said, “To provide relief to patients, particularly those suffering from cancer, rare diseases and other severe chronic diseases, I propose to add 36 lifesaving drugs and medicines to the list of medicines fully exempted from Basic Customs Duty (BCD). I also propose to add 6 lifesaving medicines to the list attracting concessional customs duty of 5 percent. Full exemption and concessional duty will also respectively apply on the bulk drugs for manufacture of the above.”

She also mentioned that medicines provided under Patient Assistance Programmes (PAPs) run by pharmaceutical companies will be fully exempt from customs duty, as long as they are supplied for free to patients. “I propose to add 37 more medicines along with 13 new patient assistance programmes,” she added.

Advertisements

37 life-saving medicines and 30 new assistance programs exempted

S.NoDrug NamePatient Assistance Program (PAP)Company Name
1Pembrolizumab KeyPAP 1.0MSD Pharmaceuticals
2Pembrolizumab KIRANMSD Pharmaceuticals
3LorlatinibLorbriquaCarePfizer Products India Pvt. Ltd.
4DacomitinibDacoCarePfizer Products India Pvt. Ltd.
5Inotuzumab OzogamicinHemaCarePfizer Products India Pvt. Ltd.
6RibociclibUMAANGNovartis Healthcare Pvt. Ltd.
7DabrafenibUMAANGNovartis Healthcare Pvt. Ltd.
8SelumetinibAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
9BenralizumabAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
10FulvestrantAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
11AcalabrutinibAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
12OlaparibAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
13AmivantamabJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
14TeclistamabJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
15UstekinumabJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
16Daratumumab + Hyaluronidase-fihjJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
17IbrutinibJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
18BortezomibJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
19DaratumumabJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
20CetuximabRainbow PAPMerck Specialties Pvt. Ltd.
21AvelumabMy Bavencio Assist ProgramMerck Specialties Pvt. Ltd.
22TepotinibMy Tepmetko Patient Access ProgramMerck Specialties Pvt. Ltd.
23Brentuximab VedotinTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
24VedolizumabTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
25Velaglucerase AlphaTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
26Agalsidase AlphaTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
27IdursulphaseTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
28MepolizumabGSK Pharmaceuticals Ltd.
29AlectinibThe Blue TreeRoche Products India Pvt. Ltd.
30Risdiplam PowderThe Blue TreeRoche Products India Pvt. Ltd.
31EmicizumabThe Blue TreeRoche Products India Pvt. Ltd.
32AtezolizumabThe Blue TreeRoche Products India Pvt. Ltd.
33Pertuzumab + TrastuzumabThe Blue TreeRoche Products India Pvt. Ltd.
34OcrelizumabThe Blue TreeRoche Products India Pvt. Ltd.
35Polatuzumab VedotinThe Blue TreeRoche Products India Pvt. Ltd.
36FaricimabThe Blue TreeRoche Products India Pvt. Ltd.
37LuspaterceptBristol-Myers Patient Assistance ProgramBristol-Myers Squibb India Pvt. Ltd.

The Finance Ministry stated, “This notification will come into effect on February 2, 2025.”

In her Budget 2024 speech, Sitharaman proposed fully exempting three cancer treatment medicines from basic customs duty to aid cancer patients. She also suggested changes to the basic customs duty for X-ray tubes and flat panel detectors used in medical X-ray machines, as part of the phased manufacturing programme to align with domestic capacity growth.

In July last year, the Health Ministry was allocated Rs 90,958.63 crore in the Union Budget 2024-25, marking a 12.9% increase compared to the previous year’s revised estimate of Rs 80,517.62 crore.

Advertisements

The financial challenges are growing as India faces a rising cancer burden. According to a study published in the Indian Journal of Medical Research, India recorded around 1.46 million new cancer cases in 2022, with lung cancer being the most common among men, and breast cancer being the most common among women.

Support us to keep independent environmental journalism alive in India.

Keep Reading

California Fires Live updates: destructive wildfires in history

Hollywood Hills burning video is fake and AI generated

Devastating wildfire in California: wind, dry conditions to blame?

Los Angeles Cracks Under Water Pressure

From tourist paradise to waste wasteland: Sindh River Cry for help

Follow Ground Report on X, Instagram and Facebook for environmental and underreported stories from the margins. Give us feedback on our email id greport2018@gmail.com. 

Don’t forget to Subscribe to our weekly newsletter, Join our community on WhatsApp, and Follow our YouTube Channel for video stories. 

Author

Support Ground Report to keep independent environmental journalism alive in India

We do deep on-ground reports on environmental, and related issues from the margins of India, with a particular focus on Madhya Pradesh, to inspire relevant interventions and solutions. 

We believe climate change should be the basis of current discourse, and our stories attempt to reflect the same.

Connect With Us

Send your feedback at greport2018@gmail.com

Newsletter

Subscribe our weekly free newsletter on Substack to get tailored content directly to your inbox.

When you pay, you ensure that we are able to produce on-ground underreported environmental stories and keep them free-to-read for those who can’t pay. In exchange, you get exclusive benefits.

Your support amplifies voices too often overlooked, thank you for being part of the movement.

EXPLORE MORE

LATEST

mORE GROUND REPORTS

Environment stories from the margins